Completed PHASE3 INTERVENTIONAL 2-arm NCT03700320

Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine

A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine

Sponsor: Allergan

Conditions Episodic Migraine

Interventions Atogepant Standard of Care (SOC) Migraine Preventive Medication

Updated 10 times since 2018 Last updated: May 20, 2021 Started: Oct 8, 2018 Primary completion: May 21, 2020 Completion: May 21, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Episodic Migraine and is currently completed. Allergan leads this study, which shows 10 recorded versions since 2018 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

10 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Sep 2021 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Sep 2021 [monthly]

Completed PHASE3

▶ Show 5 earlier versions

Jun 2020 — Jan 2021 [monthly]

Completed PHASE3

Status: Active Not Recruiting → Completed
Mar 2020 — Jun 2020 [monthly]

Active Not Recruiting PHASE3
Apr 2019 — Mar 2020 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
Dec 2018 — Apr 2019 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Nov 2018 — Dec 2018 [monthly]

Not Yet Recruiting PHASE3

First recorded

Oct 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Allergan

Data source: Allergan

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Akron, United States , Albuquerque, United States , Allentown, United States , Amherst, United States , Anaheim, United States , Anderson, United States , Ann Arbor, United States , Atlanta, United States , Austin, United States , Bardstown, United States and 92 more locations